Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
Compositions and preparations of fetal support tissue that prevent or reduce the proliferation and epithelial-mesenchymal transition (EMT) of epithelial cells, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or reducing the proliferation, cell migration, and EMT of epithelial cells in an individual in need thereof, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or treating proliferative vitreoretinopathy in an individual in need thereof.
1. A method for treating Proliferative Vitreoretinopathy (PVR) in an individual having PVR or preventing PVR in an individual who has experienced retinal detachment, comprising administering to an individual having PVR or who has experienced retinal detachment a therapeutically effective amount of an injectable composition, consisting essentially of:
(a) substantially isolated heavy chain-hyaluronic acid/pentraxin 3 complex (HC-HA/PTX3), reconstituted HC-HA/PTX3, or a combination thereof; and
(b) a pharmaceutically acceptable diluent, excipient, vehicle, or carrier.
2. The method according to claim 1 , wherein the HC-HA/PTX3 is isolated from a fetal support tissue selected from the group consisting of placenta, placental amniotic membrane, umbilical cord, umbilical cord amniotic membrane, chorion, amnion-chorion, amniotic stroma, amniotic jelly, amniotic fluid, or a combination thereof.
3. The method of claim 2 , wherein the fetal support tissue is frozen or previously frozen.
4. The method of claim 1 , wherein the therapeutically effective amount is an amount effective for preventing or reducing the proliferation, cell migration or epithelial-mesenchymal transition (EMT) of epithelial cells.
5. The method according to claim 4 , wherein the epithelial cells are retinal pigment epithelial cells (RPE).
6. The method according to claim 4 , wherein the epithelial cells are human epithelial cells.
7. The method of claim 1 , wherein the substantially isolated HC-HA/PTX3 is isolated from fetal support tissue by ultracentrifugation.
8. The method according to claim 1 , wherein the injectable composition is a gel, a solution, or a suspension.
9. The method according to claim 1 , wherein the injectable composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjunctival injection, retrobulbar injection, intracameral injection or sub-Tenon's injection.
10. A method for treating Proliferative Vitreoretinopathy (PVR) in an individual having PVR or preventing PVR in an individual who has experienced retinal detachment, comprising administering to an individual having PVR or who has experienced retinal detachment a therapeutically effective amount of an injectable composition, consisting essentially of:
(a) substantially isolated HC-HA/PTX3, reconstituted HC-HA/PTX3, or a combination thereof;
(b) an additional therapeutic agent; and
(c) a pharmaceutically acceptable diluent, excipient, vehicle, or carrier, thereby treating or preventing PVR.